Hottest Stocks (Over $10)	Hottest Stocks ($2-$10)	Biggest Losers (Over $10)	Biggest Losers ($2-$10)	Hottest Industries	Hottest Sectors	EPS / Sales Surprises
Enter Ticker Symbol:   Ticker Lookup Company Quote Company Profile Research Summary EPS Consensus Perspective Insider Transactions Price Performance

Enter any portion of the company’s name to find its corresponding ticker symbol:

Search for :

Zacks Company Profile for Pliant Therapeutics, Inc. (PLRX : NSDQ)

• Company Description    Pliant Therapeutics Inc. is a clinical stage biopharmaceutical company. It is focused on discovering and developing novel therapies for the treatment of fibrosis. The company's lead product consist PLN-74809 and PLN-1474 which are in clinical stage. Pliant Therapeutics Inc. is based in SAN FRANCISCO, Calif. Number of Employees: 91

• Price / Volume Information    Yesterday's Closing Price: $4.96 Daily Weekly Monthly 20 Day Moving Average: 253,769 shares Shares Outstanding: 36.17 (millions) Market Capitalization: $179.40 (millions) Beta: 1.13 52 Week High: $33.95 52 Week Low: $3.97 Short Interest Ratio:   % Price Change % Price Change Relative to S&P 500 4 Week -31.21% -24.67% 12 Week -48.60% -42.23% Year To Date -63.26% -55.12%

• Address & Contact Information Street Address Phone / Fax Email Address Web URL 260 LITTLEFIELD AVENUE - SOUTH SAN FRANCISCO,CA 94080 USA ph: 650-481-6770 fax: - ir@pliantrx.com http://pliantrx.com

• General Corporate Information    Officers Bernard Coulie - Chief Executive Officer;President; Hoyoung Huh - Chairman of the Board; Director Keith Cummings - Chief Financial Officer Suzanne Bruhn - Director Gayle Crowell - Director Peer Information Pliant Therapeutics, Inc. (CORR.) Pliant Therapeutics, Inc. (RSPI) Pliant Therapeutics, Inc. (CGXP) Pliant Therapeutics, Inc. (BGEN) Pliant Therapeutics, Inc. (GTBP) Pliant Therapeutics, Inc. (RGRX) Industry / Sector / Ticker Info Analyst Coverage: No Industry Group: MED-BIOMED/GENE Sector: Medical CUSIP: 729139105 SIC: 2834 Fiscal Year Fiscal Year End: December Last Reported Quarter: 03/01/22 Next Expected EPS Date: 08/08/22 Share - Related Items Shares Outstanding: 36.17 Most Recent Split Date: (:1) Beta: 1.13 Market Capitalization: $179.40 (millions)

• EPS Information     • Dividend Information Analyst Coverage: No Dividend Yield: 0.00% Current Fiscal Quarter EPS Consensus Estimate: $-0.82 Indicated Annual Dividend: $0.00 Current Fiscal Year EPS Consensus Estimate: $-3.35 Payout Ratio: Number of Estimates in the Fiscal Year Consensus: 4.00 Change In Payout Ratio: Estmated Long-Term EPS Growth Rate: % Last Dividend Paid: NA - $0.00 Next EPS Report Date: 08/08/22

• Fundamental Ratios P/E Current FY Estimate: - Trailing 12 Months: - PEG Ratio: - Price Ratios Price/Book: 1.03 Price/Cash Flow: - Price / Sales: 26.99 EPS Growth vs. Year Ago Period: -21.87% vs. Previous Quarter: -14.71% Sales Growth vs. Year Ago Period: -42.55% vs. Previous Quarter: -37.52% ROE 03/31/22 - -48.97 12/31/21 - -41.94 09/30/21 - -36.28 ROA 03/31/22 - -45.15 12/31/21 - -39.44 09/30/21 - -34.61 Current Ratio 03/31/22 - 10.12 12/31/21 - 12.44 09/30/21 - 17.68 Quick Ratio 03/31/22 - 10.12 12/31/21 - 12.44 09/30/21 - 17.69 Operating Margin 03/31/22 - -1,542.15 12/31/21 - -1,284.51 09/30/21 - -914.12 Net Margin 03/31/22 - -1,542.15 12/31/21 - -1,284.51 09/30/21 - -914.12 Pre-Tax Margin 03/31/22 - -1,542.15 12/31/21 - -1,284.51 09/30/21 - -914.12 Book Value 03/31/22 - 4.81 12/31/21 - 5.52 09/30/21 - 6.13 Inventory Turnover 03/31/22 - - 12/31/21 - - 09/30/21 - - Debt-to-Equity 03/31/22 - 0.00 12/31/21 - 0.00 09/30/21 - 0.00 Debt-to-Capital 03/31/22 - 0.00 12/31/21 - 0.00 09/30/21 - 0.00

Powered by Zacks Investment Research ©